Does PALBOCICLIB Cause Performance status decreased? 15 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Performance status decreased have been filed in association with PALBOCICLIB (Ibrance). This represents 0.0% of all adverse event reports for PALBOCICLIB.
15
Reports of Performance status decreased with PALBOCICLIB
0.0%
of all PALBOCICLIB reports
5
Deaths
2
Hospitalizations
How Dangerous Is Performance status decreased From PALBOCICLIB?
Of the 15 reports, 5 (33.3%) resulted in death, 2 (13.3%) required hospitalization.
Is Performance status decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PALBOCICLIB. However, 15 reports have been filed with the FAERS database.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Performance status decreased?
BACLOFEN (156)
LENALIDOMIDE (118)
PACLITAXEL (112)
BEVACIZUMAB (103)
SODIUM OXYBATE (103)
CARBOPLATIN (100)
DEXAMETHASONE (80)
CAPECITABINE (75)
NIRAPARIB (75)
LUMATEPERONE (68)
Which PALBOCICLIB Alternatives Have Lower Performance status decreased Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID